Jennifer Koh

San Diego
  • 12670 High Bluff Drive
  • San Diego, CA 92130
  • USA
 
 

Jennifer Koh, a partner in Latham & Watkins’ Intellectual Property Litigation Practice, represents clients in patent matters pertaining to pharmaceuticals, biotechnology, and life sciences. In particular, she represents brand pharmaceutical companies in trials and Federal Circuit appeals arising under the Hatch-Waxman Act.

Ms. Koh handles all aspects of pre-trial and trial preparation, including presenting and cross-examining fact and expert witnesses at trial. She also litigates inter partes review proceedings before the US Patent and Trademark Office (USPTO). She works closely with clients to develop intellectual property strategies and coordinate with FDA regulatory strategies.

Prior to law school, Ms. Koh conducted research in vascular and hepatic tissue engineering at Duke University and the University of California, San Diego.

Ms. Koh is the local office chair of Latham’s Women Enriching Business Committee. Ms. Koh is also a board member of the San Diego Volunteer Lawyer Program, and is regularly involved in pro bono matters supporting children, immigrants, and veterans. Ms. Koh has also guest lectured at the Rady School of Management since 2015.

A sample of the cases Ms. Koh has handled includes representing:

  • Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC in a patent suit involving a generic version of Par’s Adrenalin® brand epinephrine injection. The court ruled in Par’s favor, finding that the generic infringed all asserted patent claims, and that Par’s patents were valid.
  • Endo Pharmaceuticals Inc. in patent suits involving generic versions of Endo’s brand Nascobal® cyanocobalamin nasal spray. The parties entered consent judgments that Endo’s six patents-in-suit were valid, enforceable, and infringed.
  • Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC in a declaratory judgment patent suit relating to Par’s Orange Book-listed patents for Vasostrict® vasopressin injection. The court granted Par’s motion to dismiss and entered final judgment for Par.
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.